LAGIPRA peptide is a long-acting agonist of GIP1R. It improves insulin sensitivity by enhancing glucose handling and reduces circulating branched-chain amino acids (BCAA) and keto acids. LAGIPRA peptide holds potential for research in type 2 diabetes.

The LAGIPRA peptide, administered at 1000 nmol/kg subcutaneously, reduced hyperglycemia in Glp-1r–/– mice during an intraperitoneal glucose tolerance test but had no effect on Gipr–/– animals. At a dose of 300 nmol/kg subcutaneously, given once daily for 14 days, it slightly affected body weight (reducing it by 4%) and temporarily (within the initial 24-48 hours) reduced food intake, fasting glucose, and insulin levels.